“Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of ...

The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...

A major obstacle is the blood-brain barrier, which Kunwar described as similar to “Saran Wrap” surrounding every blood vessel in the brain. This barrier evolved to protect the brain from foreign ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Phase 1 clinical trials evaluate the safety and dosage of proposed new treatments. Further research is needed to test the oncolytic virus therapy’s effectiveness and side effects. Work also continues ...

High-grade gliomas, especially glioblastoma (GBM) and others, remain among the most aggressive brain cancers, with few ...

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...

NEW YORK (Reuters Health) - The results of a mid-development stage clinical trial suggest that an experimental pan-VEGF inhibitor called cediranib may help shrink tumors and prolong survival in ...

The blood–brain barrier functions as an evolutionarily optimized vascular “filter,” permitting limited penetration of small molecules like temozolomide while effectively excluding most biologics from ...

A modified herpes virus boosted immune T cell infiltration in glioblastoma tumors and was associated with improved survival.

May 6, 2009 — The US Food and Drug Administration (FDA) has granted accelerated approval for bevacizumab (Avastin, Genentech) for use in patients with glioblastoma that has progressed despite previous ...